Enzymatics

Beverly, United States Founded: 2006 • Age: 20 yrs Acquired By Qiagen
Enzymes and DNA kits for next-generation sequencing are manufactured.

About Enzymatics

Enzymatics is a Healthcare company based in Beverly (United States) founded in 2006 by Stephen Picone and Christopher Benoit, and was acquired by Qiagen in January 2015. Enzymes and DNA kits for next-generation sequencing are manufactured. Enzymatics has raised $3.79 million across 2 funding rounds from investors including Qiagen. The company has 140 employees. Enzymatics offers products and services including QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its competitors include Neogen, GenScript and RareCyte; 3 of its 3 listed competitors have raised funding.

Company details

Enzymatics was founded in 2006 and is based in Beverly, United States. Enzymes and DNA sample preparation kits for next-generation sequencing are produced by the company within the biotechnology sector. Custom reagents or formulations are developed to address specific customer needs. Kits compatible with Illumina and Ion Torrent platforms are supplied for NGS applications. Operations focus on reagent manufacturing and tailored solutions for sequencing workflows.

  • Headquarters Beverly, United States
  • Employees 140
  • Founders Stephen Picone, Christopher Benoit
  • Stage Acquired
  • Sectors
    Healthcare
  • Website enzymatics.com
  • Social LinkedIn X
  • Acquired by Qiagen (Jan 2015)
Key Metrics
  • Total Equity Funding
    $3.79M (USD)

    in 2 rounds

  • Latest Funding Round
    $3.79M (USD), Series A

    Aug 2013

  • Investors
  • Employee Count
    140
  • Acquired by
    Qiagen

    (Jan 2015)

Products & Services of Enzymatics

Enzymatics offers a comprehensive portfolio of products and services, including QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases.

QuantiNova DNA Polymerase
DNA Polymerase

Enzyme for qPCR and multiplex PCR applications in molecular biology.

Taq-B DNA Polymerase
DNA Polymerase

Used for standard PCR and DNA amplification reactions.

T4 DNA Ligase
Ligase

Facilitates DNA cloning and library preparation processes.

Reverse Transcriptases
RNA Enzyme

Enables cDNA synthesis for RT-PCR and RNA analysis.

Funding Insights of Enzymatics

Enzymatics has successfully raised a total of $3.79M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.79 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.79M
  • Total Rounds 2
  • Last Round Series A β€” $3.79M
  • First Round $1.6M

    (Sep 2006)

All 2 funding rounds of Enzymatics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2013$3.79MSeries A––
–
Sep 2006$1.6MDebt – Convertible––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Enzymatics

Enzymatics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Qiagen.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Products and reagents for molecular diagnostic assays are supplied.
1984qiagen.comHilden, Germany
Premium access

Investor details for Enzymatics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Enzymatics

2 people are tracked at Enzymatics (2 in leadership); the tracked headcount is 140.

NameRoleGroup
Stephen Picone
Co-Founder & CSOLeadership
Christopher Benoit
Co-Founder & COOLeadership
Premium access

Complete people profiles for Enzymatics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Enzymatics

4 dated milestones of Enzymatics across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Enzymatics is founded.
  2. Funding First funding round of $1.6M.
  3. Funding Latest funding round, Series A, of $3.8M.
  4. Exit Acquired by Qiagen.

Competitors of Enzymatics

Enzymatics has 3 listed competitors in our database, 3 of them funded. They include Neogen, GenScript and RareCyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
neogen.com1982Lansing, United States$700,0002,640
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
genscript.com2002Piscataway, United States$15M5,260
Reagents and instruments are provided for life sciences research.
rarecyte.com2009Seattle, United States$114.33M54
Developer of technologies for the analysis of rare and single cells in the blood
Premium access

Detailed competitors of Enzymatics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Enzymatics

Websites that share an audience with Enzymatics (enzymatics.com).

Similar websites

Websites whose visitors overlap most with Enzymatics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
lucigen.com
100%
View details
epibio.com
92%
View details
mclab.com
78%
#2,661,746View details
biotools.eu
77%
1.7K#10,511,342View details
bioron.net
75%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for Enzymatics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Enzymatics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Enzymatics

Enzymatics was founded in 2006.

Enzymatics is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.

Enzymatics is a funded company, having raised a total of $3.79M across 2 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $1.6M, raised on Sep 2006.

Enzymatics has 140 employees.

Enzymatics was founded in 2006 and is based in Beverly, United States. Enzymes and DNA sample preparation kits for next-generation sequencing are produced by the company within the biotechnology sector. Custom reagents or formulations are developed to address specific customer needs. Kits compatible with Illumina and Ion Torrent platforms are supplied for NGS applications. Operations focus on reagent manufacturing and tailored solutions for sequencing workflows.

Enzymatics's top competitors include Neogen, GenScript and RareCyte.

Enzymatics offers QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases.

Enzymatics has 1 investor. Key investors include Qiagen.

Yes. Enzymatics was acquired by Qiagen in January 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available